MARLBOROUGH, Mass.,
Feb. 18, 2016 /PRNewswire/
-- Hologic Inc. (Nasdaq: HOLX) announced today that a new
longitudinal study published online in advance of print in JAMA
Oncology reports that women screened for breast cancer over
multiple years using Hologic's Genius 3D MAMMOGRAPHY™ exams
benefited from a significant drop in costly and stressful
recalls.1
The findings published in JAMA Oncology provide
longitudinal evidence that the benefits of 3D MAMMOGRAPHY™ exams –
fewer women called back, more cancer cases found in recalled
patients, and fewer cancers diagnosed between regular scheduled
screenings – can be sustained and even improved over time with
consecutive use. JAMA Oncology is a monthly peer-reviewed
medical journal published by the American Medical
Association.
Emily F. Conant, MD, senior
author, and her co-researchers analyzed screening mammography
metrics for 23,958 women at the University of
Pennsylvania Hospital over a four-year period. Differences
in screening outcomes were assessed for women screened with
standard digital mammography, women screened with 3D MAMMOGRAPHY™
exams, and women screened with 3D MAMMOGRAPHY™ exams over multiple
years. The authors conclude that sustained, and even improved,
performance is possible over time when 3D MAMMOGRAPHY™ exams are
used in population-based screening.
"The new JAMA Oncology study is a significant addition to
the already substantial body of research showing that Genius™ 3D
MAMMOGRAPHY™ exams increase invasive cancer detection and reduce
the number of women recalled for additional imaging," said
Pete Valenti, Hologic's Division
President, Breast and Skeletal Health Solutions. "This new
study demonstrates that the benefits of 3D MAMMOGRAPHY™ are
sustainable, and further supports the importance and need for this
life-saving technology."
Hologic's Genius™ 3D MAMMOGRAPHY™ exams have been available in
the United States since
February 2011. In 2015 an estimated
7.5 million women in the U.S. benefited from Genius™ 3D
MAMMOGRAPHY™ exams. Additional information, as well as a
locator to find imaging sites offering the exams, can be found at
http://mygenius3d.com/
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, Genius, and the Science of Sure are
trademarks and/or registered trademarks of Hologic, Inc., and/or
its subsidiaries in the United States and/or other
countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic mammography systems. There can be no assurance the
systems will achieve the benefits described here, or that such
benefits will be replicated in any particular manner with respect
to an individual patient. The actual effect of the use of the
systems can only be determined on a case-by-case basis depending on
the particular circumstances and patient in question. In addition,
there can be no assurance that the systems will achieve any
expected level of sales or market share. Hologic expressly
disclaims any obligation to release publicly any updates to the
data or statements presented here to reflect any change in the
Company's expectations or any change in events, conditions or
circumstances on which any such data or statements are based.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
858.410.8588
Michael.watts@hologic.com
1 Elizabeth S.
McDonald, MD, PhD; Andrew Oustimov, MPH; Susan P. Weinstein, MD; Marie B. Synnestvedt, PhD; Mitchell Schnall, MD, PhD, and Emily F. Conant, MD. Effectiveness of Digital
Breast Tomosynthesis Compared with Digital Mammography. JAMA
Oncol. 2016;2(6):1-7. Doi:10:10.1001/jamoncol. 2015.5536.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-multi-year-study-in-jama-oncology-further-supports-effectiveness-of-hologics-genius-3d-mammography-exams-300222652.html
SOURCE Hologic, Inc.